Karius, Inc.
12
1
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Next Generation Pathogen Sequencing for Prediction of Adverse Events
Role: collaborator
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
Role: lead
Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Role: collaborator
The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time)
Role: lead
Detection of Dengue Virus in Plasma of Patients in Nepal
Role: lead
Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients
Role: lead
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Role: lead
Next Generation Sequencing Detection of Lyme Disease
Role: collaborator
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Role: lead
Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay
Role: lead
Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay
Role: lead
SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
Role: lead
All 12 trials loaded